» Articles » PMID: 36552017

Fourth Dose of MRNA COVID-19 Vaccine Transiently Reactivates Spike-Specific Immunological Memory in People Living with HIV (PLWH)

Abstract

: People Living With HIV (PLWH), with advanced disease, lower CD4+ T cell counts or an unsuppressed HIV viral load can have a suboptimal vaccine response. For this reason, in the current COVID-19 pandemic, they represent a prioritized population for the SARS-CoV-2 fourth (or second booster) vaccine dose. This work aims to investigate the effects of a second booster on the reactivation of the spike-specific humoral and cell-mediated immune responses in PLWH. : A total of eight PLWH, who received a fourth dose of the original mRNA vaccines were enrolled. They were evaluated before and then 7 days, 1 month and 2 months after the injection. The humoral response was assessed via a chemiluminescent immunoassay. Immunophenotyping and the functional evaluation of the SARS-CoV-2-specific cellular immune responses were performed via flow cytometry. : Anti-spike IgG levels were above the cut-off value for all subjects at all timepoints. The spike-specific CD4+ T cell response was reactivated one week after the fourth vaccine dose, and on average declined at two months post-vaccination. A similar trend was observed for the spike-specific B cells. A low percentage of spike-specific CD4+ T cells was activated by the B.1.1.529 BA.1 Omicron-spike mutated peptides, and the majority of these cells were reactive to the conserved portions of the spike protein. Similarly, the majority of the spike-specific memory B cells were able to bind both Wuhan and Omicron-spike entire protein. : Spike-specific adaptive immune responses are transiently reactivated in PLWH following the fourth mRNA vaccine dose. The breadth of the immune responses to the mutated spike protein provides insight on the possible cross-reactivity for the SARS-CoV-2 variants of concern (VOCs).

Citing Articles

The Impact of HIV on B Cell Compartment and Its Implications for COVID-19 Vaccinations in People with HIV.

Wang L, Vulesevic B, Vigano M, Assadiq A, Kang K, Fernandez C Vaccines (Basel). 2025; 12(12.

PMID: 39772034 PMC: 11679862. DOI: 10.3390/vaccines12121372.


Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV.

Baldovin T, Leoni D, Geppini R, Miatton A, Amoruso I, Fonzo M Vaccines (Basel). 2024; 12(10).

PMID: 39460338 PMC: 11512344. DOI: 10.3390/vaccines12101172.


Severe acute respiratory syndrome coronavirus 2-specific T-cell responses are induced in people living with human immunodeficiency virus after booster vaccination.

Wang X, Li Y, Jin J, Chai X, Ma Z, Duan J Chin Med J (Engl). 2024; 137(22):2734-2744.

PMID: 39028115 PMC: 11611240. DOI: 10.1097/CM9.0000000000003176.


The immunologic outcomes and adverse events of COVID-19 vaccine booster dose in immunosuppressed people: A systematic review.

SeyedAlinaghi S, Dashti M, Afzalian A, Siami H, Ghasemzadeh A, Varshochi S Prev Med Rep. 2024; 44:102778.

PMID: 38979481 PMC: 11228787. DOI: 10.1016/j.pmedr.2024.102778.


Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis.

Cheng M, Li R, Weng Z, Song G Front Med (Lausanne). 2023; 10:1275843.

PMID: 37877024 PMC: 10591097. DOI: 10.3389/fmed.2023.1275843.


References
1.
Bozzi G, Lombardi A, Ludovisi S, Muscatello A, Manganaro L, Cattaneo D . Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272. Int J Infect Dis. 2021; 113:125-126. PMC: 8520177. DOI: 10.1016/j.ijid.2021.10.021. View

2.
Ma Z, Li P, Ji Y, Ikram A, Pan Q . Cross-reactivity towards SARS-CoV-2: the potential role of low-pathogenic human coronaviruses. Lancet Microbe. 2021; 1(4):e151. PMC: 7836609. DOI: 10.1016/S2666-5247(20)30098-7. View

3.
Nordstrom P, Ballin M, Nordstrom A . Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide, retrospective cohort study in Sweden. Lancet Reg Health Eur. 2022; 21:100466. PMC: 9277096. DOI: 10.1016/j.lanepe.2022.100466. View

4.
Mazzoni A, Salvati L, Maggi L, Annunziato F, Cosmi L . Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. Semin Immunol. 2021; 55:101508. PMC: 8547971. DOI: 10.1016/j.smim.2021.101508. View

5.
Mullender C, da Costa K, Alrubayyi A, Pett S, Peppa D . SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxf Open Immunol. 2023; 3(1):iqac005. PMC: 9452103. DOI: 10.1093/oxfimm/iqac005. View